MedTrace Logo

Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma

NCT01717924 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 314

Last updated 2026-05-14

No results posted yet for this study

Summary

The ADCI 002 trial is a large multicenter phase II-III prospective randomized controlled trial comparing primary surgery versus primary chemotherapy followed by surgery in patients with a resectable signet ring cell gastric adenocarcinoma

Conditions

  • Signet Ring Cell Gastric Adenocarcinoma

Interventions

PROCEDURE

peri-operative chemotherapy

Usual treatment strategy for gastric adenocarcinoma

PROCEDURE

Surgery first

strategy with a surgical procedure first, without the usual peri-operative chemotherapy

Sponsors & Collaborators

  • Federation Francophone de Cancerologie Digestive

    collaborator OTHER

  • UNICANCER

    collaborator OTHER

  • Federation of Research in Surgery (FRENCH)

    collaborator OTHER

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Guillaume mariette, MD,PhD · FFCD, FNCLCC, FRENCH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717924 on ClinicalTrials.gov